Spinnaker Trust grew its stake in shares of Becton Dickinson and Co (NYSE:BDX) by 2.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,218 shares of the medical instruments supplier’s stock after buying an additional 296 shares during the period. Spinnaker Trust’s holdings in Becton Dickinson and were worth $3,428,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in the company. IMS Capital Management purchased a new position in Becton Dickinson and during the third quarter worth $29,000. JCIC Asset Management Inc. purchased a new position in Becton Dickinson and during the fourth quarter worth $54,000. Signet Investment Advisory Group Inc. purchased a new position in Becton Dickinson and during the fourth quarter worth $56,000. Essex Savings Bank purchased a new position in Becton Dickinson and during the fourth quarter worth $67,000. Finally, Intercontinental Wealth Advisors LLC purchased a new position in Becton Dickinson and during the fourth quarter worth $80,000. Hedge funds and other institutional investors own 86.28% of the company’s stock.

In other news, CEO Vincent A. Forlenza sold 16,866 shares of the business’s stock in a transaction on Tuesday, November 13th. The shares were sold at an average price of $237.61, for a total transaction of $4,007,530.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Thomas E. Polen, Jr. sold 5,243 shares of the business’s stock in a transaction on Monday, November 19th. The shares were sold at an average price of $243.86, for a total transaction of $1,278,557.98. The disclosure for this sale can be found here. Insiders have sold 34,606 shares of company stock valued at $8,356,772 over the last three months. Insiders own 0.12% of the company’s stock.

BDX has been the subject of several recent analyst reports. TheStreet lowered shares of Becton Dickinson and from a “b+” rating to a “c+” rating in a research note on Friday, December 7th. KeyCorp lifted their price objective on shares of Becton Dickinson and from $264.00 to $273.00 and gave the stock an “overweight” rating in a research note on Thursday, November 8th. Citigroup dropped their price objective on shares of Becton Dickinson and from $279.00 to $256.00 and set a “buy” rating for the company in a research note on Wednesday, January 2nd. Wells Fargo & Co dropped their price objective on shares of Becton Dickinson and from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, November 7th. Finally, UBS Group initiated coverage on shares of Becton Dickinson and in a research note on Tuesday, November 27th. They set a “neutral” rating and a $260.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $253.17.

Shares of BDX traded up $0.13 during trading hours on Monday, reaching $242.34. 14,362 shares of the company traded hands, compared to its average volume of 1,042,927. The firm has a market capitalization of $65.45 billion, a P/E ratio of 22.02, a P/E/G ratio of 1.70 and a beta of 1.23. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a current ratio of 0.97, a quick ratio of 0.62 and a debt-to-equity ratio of 0.83.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, February 5th. The medical instruments supplier reported $2.70 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.58 by $0.12. The firm had revenue of $4.16 billion during the quarter, compared to analyst estimates of $4.10 billion. Becton Dickinson and had a net margin of 5.69% and a return on equity of 14.65%. The business’s revenue was up 35.1% on a year-over-year basis. During the same period in the previous year, the firm earned $2.48 earnings per share. Analysts predict that Becton Dickinson and Co will post 12.1 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 29th. Stockholders of record on Friday, March 8th will be paid a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.27%. The ex-dividend date is Thursday, March 7th. Becton Dickinson and’s dividend payout ratio is currently 27.97%.

WARNING: “Becton Dickinson and Co (BDX) Stake Raised by Spinnaker Trust” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2019/02/11/becton-dickinson-and-co-bdx-stake-raised-by-spinnaker-trust.html.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: What factors cause inflation to rise?

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.